Neuphoria Therapeutics Inc.

NASDAQ: NEUP · Healthcare · Medical - Pharmaceuticals

PublicHQ Burlington, CIK 0001191070Reports USD

#578 of 1,394 Healthcare companies by revenue

EA Score

44D

FH 69DQ 11GM —SS 29

v0.1 · 55/100 weight · provisional

↑ return on assets, return on equity · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

-$10.5M

Rev growth YoY (TTM)

-140.7%

Net income (FY)

-$369.6k

Employees

Market cap

$18.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$15.6M$15.6M2025

Net income-$369.6k-$369.6k2025

Operating income-$1.1M-$1.1M2025

Total assets$28.6M$28.6M2025

Liabilities$9.6M$9.6M2025

Equity$19.0M$19.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Neuphoria Therapeutics Inc. booked $15.6M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -2.4% net margin.

Peers · Healthcare

Atossa Therapeutics, Inc.29D Harvard Apparatus Regenerative Technology Inc.42D DIAGNOS Inc.29D Defence Therapeutics Inc.——

Key facts

CEOSpyridon Papapetropoulos

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersBurlington, null

ExchangeNASDAQ: NEUP

Employees8

IPO date2021-12-16

Latest filings

8-K2026-05-26 10-Q2026-05-15 10-Q2026-02-17 8-K2026-01-08 8-K2025-12-18 8-K2025-12-17 10-Q2025-11-14 DEF 14A2025-10-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.